Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
MVRBF's Cash to Debt is ranked higher than
86% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. MVRBF: No Debt )
MVRBF' s 10-Year Cash to Debt Range
Min: 10.06   Max: No Debt
Current: No Debt

Equity to Asset 0.90
MVRBF's Equity to Asset is ranked higher than
92% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MVRBF: 0.90 )
MVRBF' s 10-Year Equity to Asset Range
Min: 0.56   Max: 0.91
Current: 0.9

0.56
0.91
F-Score: 8
Z-Score: 18.54
M-Score: -1.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 5.64
MVRBF's Operating margin (%) is ranked higher than
83% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. MVRBF: 5.64 )
MVRBF' s 10-Year Operating margin (%) Range
Min: -544.37   Max: 16.01
Current: 5.64

-544.37
16.01
Net-margin (%) -4.78
MVRBF's Net-margin (%) is ranked higher than
78% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. MVRBF: -4.78 )
MVRBF' s 10-Year Net-margin (%) Range
Min: -527.08   Max: 16.28
Current: -4.78

-527.08
16.28
ROE (%) -2.50
MVRBF's ROE (%) is ranked higher than
79% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. MVRBF: -2.50 )
MVRBF' s 10-Year ROE (%) Range
Min: -104.98   Max: 10.38
Current: -2.5

-104.98
10.38
ROA (%) -2.14
MVRBF's ROA (%) is ranked higher than
80% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. MVRBF: -2.14 )
MVRBF' s 10-Year ROA (%) Range
Min: -68.2   Max: 8.38
Current: -2.14

-68.2
8.38
ROC (Joel Greenblatt) (%) 90.01
MVRBF's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. MVRBF: 90.01 )
MVRBF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -551.07   Max: 314
Current: 90.01

-551.07
314
Revenue Growth (%) 85.90
MVRBF's Revenue Growth (%) is ranked higher than
99% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. MVRBF: 85.90 )
MVRBF' s 10-Year Revenue Growth (%) Range
Min: -50.3   Max: 85.9
Current: 85.9

-50.3
85.9
» MVRBF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MVRBF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.20
MVRBF's P/E(ttm) is ranked higher than
96% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MVRBF: 18.20 )
MVRBF' s 10-Year P/E(ttm) Range
Min: 14.33   Max: 76.94
Current: 18.2

14.33
76.94
P/B 2.90
MVRBF's P/B is ranked higher than
82% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. MVRBF: 2.90 )
MVRBF' s 10-Year P/B Range
Min: 1.61   Max: 19.44
Current: 2.9

1.61
19.44
P/S 8.30
MVRBF's P/S is ranked higher than
81% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. MVRBF: 8.30 )
MVRBF' s 10-Year P/S Range
Min: 2.42   Max: 91.61
Current: 8.3

2.42
91.61
EV-to-EBIT 94.31
MVRBF's EV-to-EBIT is ranked higher than
85% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MVRBF: 94.31 )
MVRBF' s 10-Year EV-to-EBIT Range
Min: 11   Max: 127.8
Current: 94.31

11
127.8
Current Ratio 6.27
MVRBF's Current Ratio is ranked higher than
82% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. MVRBF: 6.27 )
MVRBF' s 10-Year Current Ratio Range
Min: 1.84   Max: 10.42
Current: 6.27

1.84
10.42
Quick Ratio 6.07
MVRBF's Quick Ratio is ranked higher than
82% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. MVRBF: 6.07 )
MVRBF' s 10-Year Quick Ratio Range
Min: 1.83   Max: 10.41
Current: 6.07

1.83
10.41

Valuation & Return

vs
industry
vs
history
Price/Net Cash 114.30
MVRBF's Price/Net Cash is ranked higher than
78% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. MVRBF: 114.30 )
MVRBF' s 10-Year Price/Net Cash Range
Min: 6.75   Max: 33.97
Current: 114.3

6.75
33.97
Price/Net Current Asset Value 17.10
MVRBF's Price/Net Current Asset Value is ranked higher than
76% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. MVRBF: 17.10 )
MVRBF' s 10-Year Price/Net Current Asset Value Range
Min: 6.49   Max: 33.42
Current: 17.1

6.49
33.42
Price/Tangible Book 5.30
MVRBF's Price/Tangible Book is ranked higher than
79% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. MVRBF: 5.30 )
MVRBF' s 10-Year Price/Tangible Book Range
Min: 3.57   Max: 19.63
Current: 5.3

3.57
19.63
Price/DCF (Projected) 70.30
MVRBF's Price/DCF (Projected) is ranked higher than
82% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MVRBF: 70.30 )
MVRBF' s 10-Year Price/DCF (Projected) Range
Min: 0   Max: 0
Current: 70.3

Price/Median PS Value 1.00
MVRBF's Price/Median PS Value is ranked higher than
83% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. MVRBF: 1.00 )
MVRBF' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 11.71
Current: 1

0.37
11.71
Price/Graham Number 2.20
MVRBF's Price/Graham Number is ranked higher than
94% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MVRBF: 2.20 )
MVRBF' s 10-Year Price/Graham Number Range
Min: 1.68   Max: 3.99
Current: 2.2

1.68
3.99
Earnings Yield (Greenblatt) 1.30
MVRBF's Earnings Yield (Greenblatt) is ranked lower than
57% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. MVRBF: 1.30 )
MVRBF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 9.1
Current: 1.3

0.8
9.1
Forward Rate of Return (Yacktman) -7.27
MVRBF's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. MVRBF: -7.27 )
MVRBF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -12.2   Max: -7.3
Current: -7.27

-12.2
-7.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MVIR B.Sweden, 0GP7.country, MVR.Germany
Medivir AB is a pharmaceutical company with an R&D focus on infectious diseases and hepatitis C. The Company works with the entire development chain, from the early research to the finished pharmaceutical product on the market. Its research focuses on infectious diseases and has expertise in the chemistry and biology of the enzyme classes, polymerase and protease. The research portfolio comprises nine pharmaceutical projects, five of which are being conducted in collaboration with partners. Seven of the projects focus on the development of antiviral pharmaceuticals, of which four are conducted in the hepatitis C sphere. The protease inhibitor, simeprevir, has been developed by the Company and Janssen. Positive simeprevir phase III data was reported in December 2012 that will, together with previous phase II data, form the basis for registration applications in the USA, Europe and Japan. The Company markets pharmaceuticals in the Nordic market. The product range comprises approximately15 prescription pharmaceuticals in different therapeutic spheres. The products include Citodon, Laxabon,Lithionit, Mollipect and Paraflex. Parallel imports of pharmaceuticals to the Swedish market are conducted via the wholly owned subsidiary company, Cross Pharma.
» More Articles for OTCPK:MVRBF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide